logo
banner

Journals & Publications

Journals Publications Papers

Papers

Voxel-based Comparison of Brain Glucose Metabolism between Patients with Cushing's Disease and Healthy Subjects
Mar 19, 2018Author:
PrintText Size A A

Title: Voxel-based Comparison of Brain Glucose Metabolism between Patients with Cushing's Disease and Healthy Subjects

 Authors: Liu, S; Wang, YY; Xu, KB; Ping, F; Li, F; Wang, RZ; Cheng, X

 Author Full Names: Liu, Shuai; Wang, Yinyan; Xu, Kaibin; Ping, Fan; Li, Fang; Wang, Renzhi; Cheng, Xin

 Source: NEUROIMAGE-CLINICAL, 17 354-358; 10.1016/j.nicl.2017.10.038 2018

 Language: English

 Abstract: Cognitive impairment and psychiatric symptoms are common in patients with Cushing's disease (CD) owing to elevated levels of glucocorticoids. Molecular neuroimaging methods may help to detect changes in the brain of patients with CD. The aim of this study was to investigate the characteristics of brain metabolism and its association with serum cortisol level in CD. We compared brain metabolism, as measured using [F-18]-fluorodeoxyglucose positron emission tomography (FDG PET), between 92 patients with CD and 118 normal subjects on a voxel-wise basis. Pearson correlation was performed to evaluate the association between cerebral FDG uptake and serum cortisol level in patients with CD. We demonstrated that certain brain regions in patients with CD showed significantly increased FDG uptake, including the basal ganglia, anteromedial temporal lobe, thalamus, precentral cortex, and cerebellum. The clusters that demonstrated significantly decreased uptake were mainly located in the medial and lateral frontal cortex, superior and inferior parietal lobule, medial occipital cortex, and insular cortex. The metabolic rate of the majority of these regions was found to be significantly correlated with the serum cortisol level. Our findings may help to explain the underlying mechanisms of cognitive impairment and psychiatric symptoms in patients exposed to excessive glucocorticoids and evaluate the efficacy of treatments during follow-up.

 ISSN: 2213-1582

 IDS Number: FX6GA

 Unique ID: WOS:000426180300038

 PubMed ID: 29159047

*Click Here to View Full Record